Physician profile
Asad Bashey
NPI 1700853363
$27,401.19
in general payments reported to CMS, 2019-2025
45 companies · $2,628 in 2025
The $2,628 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $335 · 2021: $587 · 2022: $1,081 · 2023: $2,284 · 2024: $2,568 · 2025: $2,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,972 · Travel and Lodging: $427 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,972.39 |
| Travel and Lodging | $427.22 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $10,939.78 | 2019-2023 | Kyprolis, Blincyto |
| Seagen INC. | $6,767.25 | 2019-2023 | Adcetris |
| Celgene Corporation | $1,265.00 | 2019-2025 | Breyanzi, Reblozyl, Abecma |
| National Marrow Donor Program | $1,175.41 | 2022-2024 | |
| Astellas Pharma US INC | $855.10 | 2019-2025 | Cresemba |
| Kite Pharma, INC. | $726.64 | 2019-2025 | Yescarta |
| Janssen Biotech, INC. | $690.93 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Adc Therapeutics America, INC. | $486.46 | 2021-2025 | |
| Incyte Corporation | $416.56 | 2019-2025 | Jakafi, Niktimvo, Monjuvi |
| Pfizer INC. | $378.88 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $276.38 | 2022-2025 | Xpovio |
| Sanofi-Aventis U.S. LLC | $213.85 | 2022-2025 | |
| Abbvie INC. | $213.07 | 2019-2025 | Dalvance |
| Secura Bio, INC. | $194.94 | 2025 | Copiktra |
| Glaxosmithkline, LLC. | $184.72 | 2021-2024 | Ojjaara, Arexvy, Shingrix |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gamida Cell INC. | $180.00 | 2025 | Omisirge |
| Legend Biotech USA INC. | $178.76 | 2024-2025 | Carvykti |
| Genzyme Corporation | $173.33 | 2024-2025 | |
| Genentech USA, INC. | $168.59 | 2020-2025 | Venclexta, Columvi, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $161.60 | 2019-2025 | Iclusig, Livtencity |
| Iovance Biotherapeutics, INC. | $154.44 | 2025 | Amtagvi |
| Jazz Pharmaceuticals INC. | $148.51 | 2019-2024 | Defitelio, Rylaze, Zepzelca |
| Novartis Pharmaceuticals Corporation | $145.65 | 2021-2024 | |
| Sobi, INC | $135.41 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $134.30 | 2019-2025 | Prevymis |
| Regeneron Healthcare Solutions, INC. | $134.00 | 2025 | Lynozyfic |
| Daiichi Sankyo INC. | $103.85 | 2023-2025 | Vanflyta |
| Genmab U.S., INC. | $96.67 | 2024 | Epkinly |
| Janssen Scientific Affairs, LLC | $81.11 | 2021 | |
| Servier Pharmaceuticals LLC | $76.12 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $68.74 | 2021-2023 | Imbruvica |
| Blueprint Medicines Corporation | $68.13 | 2023-2025 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $66.48 | 2023-2024 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $64.85 | 2025 | |
| Epizyme, INC. | $52.14 | 2021-2022 | |
| Octapharma USA, INC. | $51.39 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Beigene USA, INC. | $41.92 | 2023-2024 | Brukinsa |
| Paratek Pharmaceuticals, INC. | $27.29 | 2022-2023 | Nuzyra |
| Rigel Pharmaceuticals, INC. | $22.65 | 2023 | Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $21.96 | 2022 | |
| Acrotech Biopharma INC. | $16.78 | 2024 | Beleodaq |
| Adaptive Biotechnologies Corporation | $16.10 | 2020 | |
| Kyowa Kirin, INC. | $13.34 | 2019 | |
| Agios Pharmaceuticals, INC. | $12.11 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Bashey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.